National Brain Tumor Society Statement on Tocagen Designation
February 23, 2017
February 23, 2017
NEWTON, Mass., Feb. 23 -- The National Brain Tumor Society issued the following news release:
Today, Tocagen, a company developing a gene therapy to treat cancer, announced that it has received "Breakthrough Therapy Designation(*)" for its lead product candidate Toca 511 & Toca FC(**) from the U.S. Food and Drug Administration (FDA) for the treatment of recurrent high-grade glioma (glioblastomas and anaplastic astrocytomas).
Tocagen was granted Breakth . . .
Today, Tocagen, a company developing a gene therapy to treat cancer, announced that it has received "Breakthrough Therapy Designation(*)" for its lead product candidate Toca 511 & Toca FC(**) from the U.S. Food and Drug Administration (FDA) for the treatment of recurrent high-grade glioma (glioblastomas and anaplastic astrocytomas).
Tocagen was granted Breakth . . .